Ataxia They Found the Gene. Let's Find the Cure.

Research News

New Grant Issued to University of Michigan Researcher

July 19th, 2009

We have awarded a $52,000 grant to Dr. Henry Paulson, MD, PhD at the University of Michigan for research entitled Testing and Optimizing Viral-mediated RNAi Strategies for SCA3.

This project has the two following aims:

1) Test the efficacy of RNAi virus that target the pathogenic Ataxin3 gene in the SCA3 transgenic mouse model.
2) Develop doxycycline-regulatable RNAi vectors, using Ataxin3 as the lead target gene.

Only in the presence of doxycycline will the RNAi molecule be expressed sufficiently to turn off the disease gene.

This research will take about 1 year.

Update on Grants

December 2008

Ataxia MJD Research Project, Inc. granted $100,000 to Dr. Ilya Bezprozvanny for research with FDA approved dantrolene and SCA3 transgenic mice. We are happy to report that Dr. Ilya Bezprozvanny’s et al published Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 3 in the November 26, 2008 issue of The Journal of Neuroscience.

Read about Dr. Bezprozvanny's findings on the UT Southwestern website in a article that is more accessible and easier to understand for the non-scientist.

Dr. Bezprozvanny has received NIH funding for further SCA3 research.

Unfortunately, Dr. Patricia Maciel’s research that we were funding entitled, Role of neuroinflammation in the pathogenesis and progression of Machado-Joseph Disease: study of a mouse model has been interrupted because of unforeseen circumstances beyond Dr. Maciel’s control.

Three Research Grants Funded

October 2006

We recently funded three MJD/SCA3 research projects.

Randall Pittman, Ph.D.,
Patricia Maciel, Ph.D.
, and
Ilya Bezprozvanny, Ph.D.

were the recipients of the three grants.

These grants were approved with the help of our scientific advisory board.

Please download our Fall 2006 Newsletter for details on the three research projects.


Copyright © 2012 Ataxia MJD Research Project, Inc.
Send mail to with your questions and comments.